Merck faces high-stakes decision on Moderna acquisition

Merck is approaching a pivotal moment as its leading cancer therapy, Keytruda, nears the end of its U.S. market exclusivity. With lower-cost competitors expected to enter the market by late 2028, Merck faces mounting pressure to identify new growth drivers before its revenue base is significantly impacted. One proposed strategy is the full acquisition of Moderna at $210-$215 per share, valuing the biotech company at approximately $86 billion.

Why Merck's Growth Strategy Is at Risk

Keytruda currently generates nearly half of Merck's total revenue, making the company unusually reliant on a single product. The introduction of Qlex, a new subcutaneous formulation of Keytruda, may help mitigate some competitive pressures, but it is unlikely to fully compensate for lost sales. Without a substantial new growth engine, Merck could experience a pronounced slowdown in earnings as generic and biosimilar alternatives become available.

Moderna's intismeran program presents a potential path forward. The vaccine is individually tailored to each patient's tumor, utilizing mRNA technology to elicit a targeted immune response. In August 2026, Merck and Moderna announced positive topline results from a Phase 3 trial of intismeran (also referred to as V940/mRNA-4157) in combination with Keytruda, achieving its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, as reported in an AP-style report. This approach could enable Merck to expand into new therapeutic areas and diversify its portfolio beyond Keytruda.

Economic Rationale for a Full Acquisition

At present, Merck and Moderna share equally in the costs and profits of the intismeran program. Acquiring Moderna outright would provide Merck with full control over the program's economics, technology, and manufacturing capabilities. This integration could accelerate the development and delivery of personalized cancer vaccines, allowing Merck to oversee the entire process from tumor analysis to vaccine production and distribution within a matter of weeks.

Market Context and Investor Implications

As of April, Moderna shares were trading near $144, a significant increase from the $24.15 level recommended by certain investment portfolios in late 2025. The proposed acquisition would value Moderna at approximately $86 billion, reflecting both its current pipeline and the potential for future advances in cancer immunotherapy. Merck's financial position and Moderna's valuation could support a combined debt-and-equity transaction of this magnitude.

In 2025, Keytruda generated billions in annual revenue for Merck, underscoring the urgency of identifying a successor as the patent expiration approaches. The pharmaceutical sector has witnessed a series of large-scale acquisitions as companies seek to secure next-generation therapies and maintain market share. Investors should carefully consider the risks associated with integration, execution, and regulatory approval, alongside the potential for sustained growth and innovation.

Personalized cancer vaccines represent a significant departure from conventional, uniform treatment approaches. By analyzing the genetic profile of individual tumors, companies such as Moderna aim to develop vaccines that train the immune system to target cancer cells unique to each patient. While this strategy is still undergoing clinical validation, and questions remain regarding cost, scalability, and long-term outcomes, the potential of personalized medicine is substantial. However, the challenges of bringing these therapies to market at scale remain considerable for both investors and patients.